Abstract
A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonel replacement therapy and calcitonin not only prevented postmenopausal bone loss but resulted in a significant 10% gain in bone mass (P <0.001).
Original language | English |
---|---|
Pages (from-to) | 53-57 |
Number of pages | 5 |
Journal | European Journal of Obstetrics and Gynecology and Reproductive Biology |
Volume | 47 |
Issue number | 1 |
DOIs | |
Publication status | Published - Oct 23 1992 |
Keywords
- Bone loss
- Calcitonin
- HRT
ASJC Scopus subject areas
- Obstetrics and Gynaecology
- Reproductive Medicine